KEY TAKEAWAYS
- The study aimed to investigate the role of anoikis in patients with DLBCL, shedding light on its implications for metastasis and aggressiveness.
- Researchers noticed that the ARG-based signature offers a promising avenue for improving prognosis prediction and treatment optimization.
Although anoikis plays a role in cancer metastasis and aggressiveness, it has rarely been reported in diffuse large B-cell lymphoma (DLBCL).
Mingze Guan and the team aimed to fill this gap by investigating the significance of anoikis in DLBCL.
Researchers performed an inclusive analysis utilizing RNA sequencing data and matched clinical information sourced from the GEO database. An anoikis-related genes (ARGs)-based risk signature was developed in the GSE10846 training cohort and subsequently validated in 3 additional cohorts. Furthermore, the half-maximal inhibitory concentration (IC50) of drugs was predicted using a bioinformatics method, and the actual IC50 values for some chemotherapy drugs were obtained via cytotoxicity assay.
About the study results, the high-risk group, as determined by the signature, demonstrated a correlation with poorer prognosis and an immunosuppressive environment in DLBCL. Additionally, the nomogram based on 8 variables displayed superior prognostic forecasting ability compared to the international prognostic index in DLBCL.
Prediction of IC50 indicated heightened sensitivity to doxorubicin (1), IPA-3 (2), lenalidomide (3), gemcitabine (4), and CEP.701 (5) in patients with DLBCL classified as high-risk by the signature, while those in the low-risk group showed sensitivity to cisplatin (6) and dasatinib (7). Consistent with the prediction, the cytotoxicity assay affirmed higher sensitivity to doxorubicin and gemcitabine and lower sensitivity to dasatinib in the high-risk group in DLBCL.
The study concluded that the ARG-based signature offers a promising direction for enhancing prognosis prediction and optimizing treatment strategies for patients with DLBCL.
This study was sponsored by National Natural Science Foundation of China, Doctoral Startup Scientific Research Foundation of Liaoning Province and 1+X program for clinical competency enhancement-improvement of MDT project, Dalian Medical University.
Source: https://pubmed.ncbi.nlm.nih.gov/38709202/
Guan M, Zhao H, Zhang Q, et al. (2024). “A novel anoikis-related signature predicts prognosis risk and treatment responsiveness in diffuse large B-cell lymphoma.” Expert Rev Mol Diagn. 2024 May;24(5):439-457. doi: 10.1080/14737159.2024.2351465. Epub 2024 May 11. PMID: 38709202.
